Multidisciplinary Approaches to Biomarker Testing in Advanced NSCLC
Hematology-Oncology
Curriculum:
Multidisciplinary Approaches to Biomarker Testing in Advanced NSCLC: A Serial Learning Approach to Bridging Communication and Educational Gaps
Multidisciplinary Approaches to Biomarker Testing in Advanced NSCLC: A Serial Learning Approach to Bridging Communication and Educational Gaps
Credits:
1.5 AMA PRA Category 1 Credit(s) ™
1.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
October 09, 2014
October 09, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
pulmonologists, pathologists, interventional radiologists, medical oncologists, thoracic surgeons, advanced practitioners, other health-care professionals involved in the treatment or management of advanced NSCLC
Relevant Terms:
ALK, Anaplastic Lymphoma Kinase, Biomarkers, Biomarker Testing, EGFR, Epidermal Growth Factor Receptor, Lung Cancer, Non-small Cell Lung Cancer, NSCLC
Corey J. Langer, MD, FACP
Corey J. Langer, MD, FACP
Professor of Medicine
Hematology/Oncology Division
University of Pennsylvania
Philadelphia, Pennsylvania
Bio
Corey J. Langer, MD, FACP, is a Professor of Medicine in the Hematology/Oncology Division at the University of Pennsylvania in Philadelphia, where he serves as Director of Thoracic Oncology in the Abramson Cancer Center and co-leads its Translational Therapeutics Program. Dr. Langer received his Doctor of Medicine degree from Boston University and completed his internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania in Philadelphia. Additional postgraduate training included a hematology/oncology fellowship at the Penn Presbyterian Medical Center and an oncology fellowship at American Oncologic Hospital, Fox Chase Cancer Center, in Philadelphia.
Dr. Langer is a fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the International Association for the Study of Lung Cancer (IASLC). He serves as Vice-Chairman of the Radiation Therapy Oncology Group (RTOG) and chairman of its Medical Oncology Subcommittee and maintains a leadership role as RTOG transitions into the NRG Cooperative Group. He also serves on the core thoracic and head and neck committees of both the Eastern Cooperative Oncology Group and RTOG. He serves on the Ethics Committee of the IASLC, and is a member of the Data Safety Monitoring Board of the Southwest Oncology Group.
Dr. Langer has contributed numerous articles and abstracts to the medical literature. His work on head and neck squamous cell cancer, non–small cell lung cancer, small cell carcinoma of the lung, and malignant mesothelioma has appeared in The New England Journal of Medicine, Seminars in Oncology, Clinical Cancer Research, the Journal of Clinical Oncology, the Journal of Thoracic Oncology, Clinical Lung Cancer, Cancer, Lung Cancer, Cancer Investigation, and the European Journal of Cancer. His work has also been presented at the national meetings of ASCO, AACR, the American Society of Hematology, and the IASLC. He has served three separate terms as a member of the editorial board of the Journal of Clinical Oncology and is currently on the editorial boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology.
| 1. | Demonstrate the importance of biomarker testing in patients with advanced NSCLC | 2. | Explain current and emerging evidence supporting targeted therapy for the treatment of patients with NSCLC |
| 3. | Identify appropriate treatment according to biomarker status to personalize therapy for patients with NSCLC | 4. | Review recent clinical trial data evaluating targeted agents for the treatment of advanced NSCLC |
| 5. | Apply expert recommendations for developing and implementing successful multidisciplinary approaches for treating patients with NSCLC |
| 1. | Demonstrate the importance of biomarker testing in patients with advanced NSCLC |
| 2. | Explain current and emerging evidence supporting targeted therapy for the treatment of patients with NSCLC |
| 3. | Identify appropriate treatment according to biomarker status to personalize therapy for patients with NSCLC |
| 4. | Review recent clinical trial data evaluating targeted agents for the treatment of advanced NSCLC |
| 5. | Apply expert recommendations for developing and implementing successful multidisciplinary approaches for treating patients with NSCLC |
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. |
Physician Continuing Medical Education
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
Credits will be awarded automatically upon passing each activity post-test with a grade of 70% or better and completion of each activity evaluation.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity. Corey J. Langer, MD, FACP, reported a financial interest/relationship or affiliation in the form of: grant/research support, Bristol-Myers Squibb Company, Pfizer, Inc., Eli Lilly and Company, Genentech, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma US, Inc.), Merck & Co., Inc., GlaxoSmithKline plc., and Nektar Therapeutics; scientific advisor, Bristol-Myers Squibb Company, ImClone LLC, sanofi US, Pfizer, Inc., Eli Lilly and Company, Amgen, Inc., AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Genentech, Inc., Bayer/Onyx, Abraxis BioScience, LLC, Abbott Laboratories, Morphotek, Inc., Biodesix, Inc., Clarient, Caris Life Sciences, Inc., Vertex Pharmaceuticals, Synta Pharmaceuticals Corp., Celgene Corporation, and Boehringer Ingelheim; speaker’s bureau, Eli Lilly and Company, Genentech, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma US, Inc.), and ImClone LLC - BMS; and data safety monitoring committee, Eli Lilly and Company, Amgen, Inc., Synta Pharmaceuticals Corp., and Agennix.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Deborah Middleton, MS, and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
ESTIMATED TIME TO COMPLETE ACTIVITY: 1 hour 30 minutes
FEE STATEMENT
There is no fee for this educational activity.
CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.
Jointly provided by:
FEE STATEMENT
There is no fee for this educational activity.
CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.
Jointly provided by:
This activity is supported by an independent educational grant from Genentech.
